Business Wire

Lenovo Integrates AI and Robotics to Deliver Smarter Retail Solutions

10.1.2025 15:00:00 CET | Business Wire | Press release

Share

Three new offerings transform delivery, customer communication and checkout services in retail and hospitality settings with proven, measurable ROI

Lenovo today introduced three new retail solutions that combine the best of robotics and artificial intelligence technologies. Premiering at NRF 2025 in New York City, each solution has been field-tested and proven in commercial settings.

Lenovo Retail Content Management Services enables retailers to create, schedule and display digital content across screens store-wide, streamlining multimedia content management and enabling real-time updates and targeted messaging to drive awareness, interest and incremental sales. The complete solution comprises all hardware and software needed, and can be deployed, maintained and managed across multiple locations globally.

A leading food and beverage chain has deployed this content management service across 100+ stores and achieved substantial cost savings from dynamically managed promotional campaigns, reduced use of paper marketing materials, and reduced manpower needed to manage both campaigns and devices.

Lenovo Retail Robotics with Yunji offers automated, independent deliveries of food, guest supplies, room services, and small packages to customers in hotels and malls. By integrating software and services with modular robots, the solution aims to enhance customer satisfaction, improve logistics efficiency, and enable smarter resource management.

This is an advancement to traditional retail robots in three ways. First, this modular design of the robot enables easy customization to a wide range of applications, unlike other robots that are locked into performing a single task. Second, AI, navigation and vision recognition enable high-quality interactions with customers that, combined with reduced delivery times, enable increased customer satisfaction. Third, it collects data as it works, enabling an AI-driven feedback loop that can be integrated into the supply chain, customer service and merchandising decision-making platforms.

The robotics solution, launched in partnership with Yunji Technology, has proven itself in real-world settings. Deployed in a 400-room hotel, for example, it handled more than 90% of guest requests and takeout services, which greatly saved on manpower and time while increasing sales revenue by 20%. Yunji’s robotics solutions are also currently deployed by more than 30,000 hotels, including those of Hilton Hotels & Resorts, Huazhu Group, InterContinental Hotels Group, Jinjiang Group, and Marriott Hotels & Resorts.

“While there is a lot of hype around AI and other technologies, examples of deployment in practical solutions that deliver measurable business outcomes is much rarer,” said Lawrence Yu, General Manager of Global Retail Solutions at Lenovo. “Today’s retailers have never faced greater challenges and have never needed technology to work for them more. Lenovo’s track record in the retail industry, working with some of the world’s biggest name retailers, means we can design, deploy and manage cutting-edge retail and hospitality solutions with low CapEx and high confidence.”

Meeting the AI challenge in retail

Deploying complex IT such as AI securely and responsibly and with maximized demonstrable return on investment remains a significant challenge for businesses in the retail sector.

Lenovo AI Fast Start addresses this challenge and helps retailers prove the business value of use cases on personal AI, enterprise AI and public AI platforms within weeks. It gives access to AI assets, experts and partners that will help retailers rapidly build a Gen AI use case solution securely with their own data and tailor it to their unique needs, speeding progress to full implementation.

A range of additional Lenovo TruScale as a Service offerings enable deployment of AI at scale, with speed and flexibility – and low CapEx costs. Lenovo TruScale Device as a Service (DaaS) provides a comprehensive AI devices portfolio and frees up valuable IT resources with a predictable, scalable subscription-based model. TruScale DaaS allows for quicker upgrades without upfront costs.

Lenovo TruScale Infrastructure as a Service (IaaS) combines the advantages of on-premises infrastructure with the flexibility of a cloud-like experience. Lenovo offers retailers tailored solutions for hybrid and multi-cloud environments, infinite storage, and high-performance computing (HPC). Lenovo’s new TruScale GPU as a Service offering enhances TruScale for HPC with advanced workload orchestration and usage metering, ensuring availability and maximizing productivity of AI-critical GPU resources.

“Although global retail sales are projected to recover in 2025, low consumer confidence is slated to continue plaguing the industry. It behooves retailers to capture this growth opportunity, by optimizing costs and boosting customer satisfaction with AI,” said Lawrence Yu. “Through relying on Lenovo’s deep retail expertise, our industry-leading, scalable hybrid AI approach, and our ability to deliver globally, today’s retailer can considerably improve their chances of sustainable success.”

Visit Lenovo at NRF 2025 exhibiting at booths #3665 and #3877.

For more information on Lenovo Retail Solutions, please visit https://techtoday.lenovo.com/us/en/solutions/retail.

About Lenovo

Lenovo is a US$57 billion revenue global technology powerhouse, ranked #248 in the Fortune Global 500, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver Smarter Technology for All, Lenovo has built on its success as the world’s largest PC company with a full-stack portfolio of AI-enabled, AI-ready, and AI-optimized devices (PCs, workstations, smartphones, tablets), infrastructure (server, storage, edge, high performance computing and software defined infrastructure), software, solutions, and services. Lenovo’s continued investment in world-changing innovation is building a more equitable, trustworthy, and smarter future for everyone, everywhere. Lenovo is listed on the Hong Kong stock exchange under Lenovo Group Limited (HKSE: 992) (ADR: LNVGY). To find out more visit https://www.lenovo.com, and read about the latest news via our StoryHub.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250110810803/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye